Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 3/20 | 0.52 |
| ▸ | DGKZ | Q13574 | 3/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | FPR2 | P25090 | 4/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.37 |
| ▸ | SCD | O00767 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133750 | 1.00 | DGKA (0.52) | DGKADGKZCHRM4HRH3FPR2 | |
| SCHEMBL23527307 | 0.94 | DGKA (0.46) | DGKADGKZCHRM4HRH3FPR2 | |
| SCHEMBL31133650 | 0.94 | DGKA (0.46) | DGKADGKZCHRM4HRH3FPR2 | |
| SCHEMBL31133498 | 0.94 | HRH3 (0.47) | DGKADGKZHRH3FPR2PROKR1 | |
| SCHEMBL23527095 | 0.94 | HRH3 (0.47) | DGKADGKZHRH3FPR2PROKR1 | |
| SCHEMBL31133736 | 0.94 | DGKA (0.46) | DGKADGKZCHRM4HRH3FPR2 | |
| SCHEMBL23527004 | 0.94 | DGKA (0.46) | DGKADGKZCHRM4HRH3FPR2 | |
| SCHEMBL23527042 | 0.93 | DGKA (0.45) | DGKADGKZCHRM4HRH3FPR2 | |
| SCHEMBL31133628 | 0.93 | DGKA (0.45) | DGKADGKZCHRM4HRH3FPR2 | |
| SCHEMBL23526862 | 0.93 | DGKA (0.47) | DGKADGKZCHRM4HRH3SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | claimed |
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | claimed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | claimed |
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | disclosed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | DGKA 1/4885DGKZ 2/4885CHRM4 1492/4885 |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | DGKA 1/4885DGKZ 2/4885CHRM4 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.